

CHANGE IN AND UPDATE ON THE USE OF PROCEEDS FROM PLACEMENT OF 562,500,000 NEW ORDINARY SHARES IN THE SHARE CAPITAL OF OUE LIPPO HEALTHCARE LIMITED

The Board of Directors of OUE Lippo Healthcare Limited (the “**Company**”) (the “**Board**”) refers to the announcements of the Company dated 10 January 2018, 12 February 2018, and 19 February 2018, in relation to the issuance of 562,500,000 new ordinary shares in the share capital of the Company pursuant to a placement agreement entered into with Brownly Healthcare Pte Ltd. (the “**Placement Announcements**”).

Capitalised terms used herein shall have the definitions ascribed to them in the Placement Announcements, unless otherwise stated or the context otherwise requires.

The Board wishes to provide an update on the reallocation and use of the Net Proceeds from the Placement of approximately S\$77.45 million (the “**Net Proceeds**”).

The Company wishes to announce that S\$26,000,000 and S\$1,275,000 of the Net Proceeds originally allocated for general working capital has been allocated towards the repayment of loans and borrowings, and the development of healthcare business and healthcare related projects, respectively.

The Board is of the view that such reallocation of the Net Proceeds is in the best interests of the Company and its shareholders as this will reduce the borrowing costs of the Company and is in line with the Group’s expansion plans.

As at the date of this announcement, the reallocation and use of the Net Proceeds are as follows:

Use of Net Proceeds	Original Amount Allocated (S\$’000)	Amount allocated pursuant to the reallocation (S\$’000)	Amount Utilised (S\$’000)	Amount unutilised (S\$ ’000)
Repayment of loans & borrowings	-	26,000	6,000	20,000
General working capital ⁽¹⁾	38,725	11,450	513	10,937
Development of healthcare business and healthcare related projects	38,725	40,000	-	40,000
Total	77,450	77,450	6,513	70,937

Note:

(1) Utilised for payroll, bank interests, legal and other professional fees.

The Company will make further announcement(s) on the use of the remaining Net Proceeds as and when they are materially disbursed.

By Order of the Board

Dr. Wong Weng Hong
Chief Executive Officer and Executive Director

14 March 2018

OUE Lippo Healthcare Limited

Company Registration No. 201304341E

(In receivership over charged shares in certain subsidiaries)

6 Shenton Way, #10-09A, OUE Downtown 2, Singapore 068809 **T:** +65 6578 9188 **F:** 64794647

www.ouelh.com

This announcement has been prepared by OUE Lippo Healthcare Limited (formerly known as International Healthway Corporation Limited) (the “Company”) and its contents have been reviewed by PrimePartners Corporate Finance Pte. Ltd. (the “Sponsor”), for compliance with the Singapore Exchange Securities Trading Limited (the “SGX-ST”) Listing Manual Section B: Rules of Catalist. The Sponsor has not verified the contents of this announcement. This announcement has not been examined or approved by the SGX-ST. The Sponsor and the SGX-ST assume no responsibility for the contents of this announcement, including the accuracy, completeness or correctness of any of the information, statements or opinions made or reports contained in this announcement.

The contact person for the Sponsor is Ms Gillian Goh, Director, Head of Continuing Sponsorship (Mailing address: 16 Collyer Quay, #10-00 Income at Raffles, Singapore 049318 and E-mail: sponsorship@ppcf.com.sg).

OUE Lippo Healthcare Limited

Company Registration No. 201304341E

(In receivership over charged shares in certain subsidiaries)

6 Shenton Way, #10-09A, OUE Downtown 2, Singapore 068809 **T:** +65 6578 9188 **F:** 64794647

www.ouelh.com